Creative Medical Technology (NASDAQ:CELZ) Releases Earnings Results, Misses Estimates By $0.43 EPS

Creative Medical Technology (NASDAQ:CELZ) released its quarterly earnings results on Friday. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.43), FiscalAI reports. The firm had revenue of $0.00 million during the quarter.

Creative Medical Technology Stock Down 2.1%

Shares of NASDAQ CELZ opened at $1.84 on Friday. Creative Medical Technology has a 52 week low of $1.50 and a 52 week high of $6.25. The firm has a 50-day moving average price of $1.93 and a 200 day moving average price of $2.62. The stock has a market capitalization of $4.75 million, a price-to-earnings ratio of -0.63 and a beta of 2.09.

Analyst Upgrades and Downgrades

CELZ has been the topic of several recent research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Creative Medical Technology in a research note on Monday, December 29th. Wall Street Zen downgraded shares of Creative Medical Technology from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce”.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Creative Medical Technology stock. Jane Street Group LLC bought a new stake in shares of Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 30,205 shares of the company’s stock, valued at approximately $59,000. Jane Street Group LLC owned about 1.17% of Creative Medical Technology as of its most recent filing with the SEC. 1.42% of the stock is owned by institutional investors and hedge funds.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc (NASDAQ: CELZ) is a clinical‐stage biotechnology company focused on the development, manufacture and commercialization of exosome‐based therapies derived from human bone marrow mesenchymal stem cells. The company’s proprietary exosome platform is being investigated for applications in regenerative medicine, aesthetic dermatology, wound healing and anti‐inflammatory treatments. Creative Medical leverages cGMP manufacturing processes to produce sterile, cell‐free exosome formulations designed to support tissue repair and cellular rejuvenation.

The company’s lead product candidates include XoFlo, an exosome enrichment product intended for use in musculoskeletal and soft tissue injuries, and specialized formulations targeting skin rejuvenation and scar reduction.